Parmax Pharma Ltd
Incorporated in 1994, Parmax Pharma Ltd manufactures bulk drugs, drugs intermediates, and specialty chemicals[1]
- Market Cap ₹ 11.2 Cr.
- Current Price ₹ 29.8
- High / Low ₹ 36.6 / 24.2
- Stock P/E
- Book Value ₹ 8.50
- Dividend Yield 0.00 %
- ROCE 3.94 %
- ROE -1.69 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 3.51 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 5.31% over past five years.
- Promoter holding is low: 30.8%
- Company has a low return on equity of 4.58% over last 3 years.
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.89 | 11.99 | 20.92 | 26.17 | 18.24 | 15.40 | 13.18 | |
0.00 | 0.03 | 0.02 | 0.02 | 0.05 | 0.05 | 10.81 | 10.88 | 19.15 | 22.74 | 15.67 | 13.12 | 14.91 | |
Operating Profit | 0.00 | -0.03 | -0.02 | -0.02 | -0.05 | -0.05 | 1.08 | 1.11 | 1.77 | 3.43 | 2.57 | 2.28 | -1.73 |
OPM % | 9.08% | 9.26% | 8.46% | 13.11% | 14.09% | 14.81% | -13.13% | ||||||
0.00 | 0.00 | 0.06 | 0.06 | 0.06 | 0.06 | 0.05 | 0.05 | 0.10 | 0.09 | 0.06 | 0.04 | 0.04 | |
Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.03 | 0.13 | 0.37 | 0.39 | 0.40 | 0.51 |
Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.09 | 1.03 | 1.01 | 1.94 | 1.93 | 1.88 | 1.77 |
Profit before tax | 0.00 | -0.03 | 0.04 | 0.04 | 0.01 | 0.01 | 0.00 | 0.10 | 0.73 | 1.21 | 0.31 | 0.04 | -3.97 |
Tax % | 0.00% | 0.00% | 25.00% | 200.00% | 100.00% | 20.00% | 41.10% | 38.02% | 54.84% | 375.00% | |||
0.00 | -0.03 | 0.04 | 0.02 | 0.00 | -0.01 | 0.00 | 0.08 | 0.43 | 0.75 | 0.14 | -0.10 | -4.13 | |
EPS in Rs | -0.08 | 0.10 | 0.05 | 0.00 | -0.03 | 0.00 | 0.21 | 1.15 | 2.00 | 0.37 | -0.27 | -11.04 | |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 5% |
3 Years: | -10% |
TTM: | -18% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -1152% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 11% |
3 Years: | -15% |
1 Year: | -4% |
Return on Equity | |
---|---|
10 Years: | 3% |
5 Years: | 5% |
3 Years: | 5% |
Last Year: | -2% |
Balance Sheet
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 3.90 | 3.90 | 3.90 | 4.03 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 |
Reserves | 0.09 | 0.06 | 0.09 | 0.12 | 0.11 | 0.10 | 0.11 | 0.18 | 0.61 | 1.37 | 1.51 | 1.40 | -1.27 |
0.87 | 0.90 | 0.92 | 0.79 | 0.46 | 1.02 | 1.96 | 5.52 | 5.26 | 5.89 | 5.18 | 5.37 | 5.49 | |
0.08 | 0.08 | 0.09 | 0.04 | 0.06 | 2.14 | 10.11 | 9.56 | 10.75 | 11.01 | 6.83 | 6.39 | 6.77 | |
Total Liabilities | 4.94 | 4.94 | 5.00 | 4.98 | 5.08 | 7.71 | 16.63 | 19.71 | 21.07 | 22.72 | 17.97 | 17.61 | 15.44 |
2.53 | 2.53 | 2.53 | 2.53 | 2.53 | 2.72 | 5.86 | 4.92 | 9.64 | 10.84 | 10.44 | 9.50 | 9.11 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.33 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.20 | 0.20 | 0.20 | 0.00 | 0.00 | 0.00 |
2.41 | 2.41 | 2.47 | 2.45 | 2.55 | 4.99 | 10.77 | 11.26 | 11.23 | 11.68 | 7.53 | 8.11 | 6.33 | |
Total Assets | 4.94 | 4.94 | 5.00 | 4.98 | 5.08 | 7.71 | 16.63 | 19.71 | 21.07 | 22.72 | 17.97 | 17.61 | 15.44 |
Cash Flows
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0.00 | -0.03 | -0.01 | -0.06 | 0.00 | -0.50 | 3.88 | 0.92 | 2.82 | 3.53 | 0.75 | 0.33 | |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.19 | -4.23 | -3.41 | -2.40 | -3.15 | -1.53 | -0.94 | |
0.00 | 0.03 | 0.01 | 0.00 | 0.10 | 0.56 | 1.14 | 3.10 | -0.23 | 0.40 | -0.91 | -0.04 | |
Net Cash Flow | 0.00 | 0.00 | 0.00 | -0.06 | 0.09 | -0.14 | 0.79 | 0.61 | 0.20 | 0.78 | -1.69 | -0.65 |
Ratios
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 60.48 | 35.01 | 57.58 | 23.01 | 13.61 | 14.69 | ||||||
Inventory Days | 203.34 | 278.66 | 88.17 | 107.27 | 154.80 | 286.55 | ||||||
Days Payable | 609.39 | 645.07 | 311.84 | 269.40 | 299.82 | 309.82 | ||||||
Cash Conversion Cycle | -345.57 | -331.40 | -166.09 | -139.12 | -131.41 | -8.57 | ||||||
Working Capital Days | -59.86 | -71.84 | -56.18 | -48.26 | -36.02 | -0.47 | ||||||
ROCE % | -0.62% | 0.82% | 0.81% | 0.20% | 0.19% | 0.66% | 1.56% | 8.40% | 14.34% | 6.13% | 3.94% |
Documents
Announcements
-
Compliance Certificate Pursuant To Regulation 7(3)
12 Apr - Compliance Certificate pursuant to Regulation 7(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 for the year ended on 31st March, 2024
-
Compliance Certificate Pursuant To Regulation 7(3)
12 Apr - Compliance Certificate pursuant to Regulation 7(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 for the year ended on 31st March, 2024
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
7 Apr - Certificate under regulation 74(5) SEBI (Depositories and Participants) regulations, 2018, For the quarter ended on 31st March, 2024.
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 2 Apr
- Closure of Trading Window 28 Mar
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
Business Overview:[1]
Company used to do manufacturing bulk drugs and specialty chemicals but it discontinued its business activities for a few years. It deals in active pharmaceutical ingredients and Contract Manufacturing Operations. It plans to extend its activity to the formulation of Tablets, Ointments,
Capsules, and Injectables.